Exploring Vaccines Targeting Fentanyl and Heroin Overdoses as a Solution to the Opioid Epidemic

Abstract

Researchers at the University of Montana are advancing the development of vaccines aimed at preventing overdoses from fentanyl and heroin. With an anticipated initiation of Phase 1 human trials in 2024, these vaccines represent a significant step in addressing the ongoing opioid crisis that has led to over 106,000 overdose deaths in the United States in 2021. This article outlines the vaccine mechanisms, the research team’s approach, and the implications for public health.

Heroin Use Equipment

Heroin Use Equipment

Introduction

The opioid epidemic, particularly the rise in fatalities associated with synthetic opioids such as fentanyl, has reached critical levels in the United States and Canada. According to the National Institutes of Health, 71,000 of the 106,000 overdose deaths in 2021 were attributed to synthetic opioids. In response to this public health crisis, researchers at the University of Montana (UM) are preparing to initiate human trials for vaccines designed to prevent heroin and fentanyl overdoses.

Read Also: Heroin Addiction Latest Facts: All You Need to Know About How to Treat It and Avoid Relapsing

Vaccine Development and Mechanism

The vaccines being developed aim to elicit an immune response that produces antibodies capable of neutralizing heroin and fentanyl without interfering with critical medications used in opioid addiction treatment, such as methadone and buprenorphine. Dr. Jay Evans, director of the UM Center for Translational Medicine and co-founder of Inimmune, outlines the collaborative efforts in designing these vaccines, which build upon a decade of research led by Dr. Marco Pravetoni at the University of Washington.

The vaccines incorporate a patented adjuvant, INI-4001, which enhances the immune response and aims to provide a stronger and more durable immunity against these opioids. The preclinical studies have demonstrated the vaccines’ effectiveness in animal models, including mice, rats, and pigs, and have resulted in publications detailing the successes of the TLR7/8 adjuvant in improving the vaccine’s efficacy.

Human Clinical Trials

The Phase 1 clinical trials are set to commence in 2024, with an initial focus on the heroin vaccine, followed by the fentanyl vaccine. These trials will assess the safety and preliminary efficacy of the vaccines, utilizing a dose-escalation strategy to identify the lowest effective dose. Recruitment for these trials will involve individuals with a history of heroin or fentanyl use, a population with a relapse rate of approximately 90%.

Dr. Evans emphasizes the importance of gradual dose escalation, highlighting that the safety of the vaccines will be paramount during the initial phases. A data safety monitoring board will review the outcomes at each dose level before progressing to higher doses.

Read Also: Hope in the Midst of Tragedy: How We Can Tackle the Opioid Crisis in the USA in 2023

Public Health Implications

The potential impact of these vaccines on public health is profound, particularly given the increasing overdose rates associated with opioids. By targeting the immune response, these vaccines could provide an innovative method for preventing overdoses, potentially saving lives and assisting individuals seeking treatment for substance use disorders.

Future Directions

The UM research team, supported by a $33.4 million contract from the National Institutes of Health, anticipates a rigorous path toward the final approval of these vaccines. Future phases of the clinical trials will focus on determining the optimal dosing regimen and the longevity of the immune response. As the development of these vaccines progresses, the team remains committed to addressing various infectious diseases and conditions, further expanding their research portfolio.

Read Also: Mental Health: 8 Effective Strategies To Break The Addiction Cycle

Conclusion

The upcoming human trials for the fentanyl and heroin vaccines represent a promising advancement in the fight against the opioid crisis. With a robust research framework and the potential for significant public health impact, these vaccines could be pivotal in addressing the challenges posed by opioid addiction and overdose.

References

Shimek, C. (2023, August 29). UM Researchers Prep Fentanyl, Heroin Vaccines for Human Trials. University of Montana News. Retrieved from https://www.umt.edu/news/2023/08/082923fent.php

FEEDBACK:

Want to live your best life?

Get the Gilmore Health Weekly newsletter for health tips, wellness updates and more.

By clicking "Subscribe," I agree to the Gilmore Health and . I also agree to receive emails from Gilmore Health and I understand that I may opt out of Gilmore Health subscriptions at any time.